缺血性卒中后长期结局因房颤表型而异
这项日本全国性队列研究纳入21,586例出院时处方口服抗凝药的房颤相关缺血性卒中存活者,按房颤检测时机与既往抗凝状态分为AFIDA、OAC-naive AF和AFDAS三型。随访显示AFIDA的5年卒中/系统性栓塞累积发生率最高(18.6%),AFDAS最低(10.5%),提示不同房颤表型预后异质。
要点
- AFIDA患者复发卒中/系统性栓塞风险显著高于OAC-naive AF(aSHR 1.38)。
- AFDAS患者复发风险低于OAC-naive AF(aSHR 0.87)。
- AFIDA患者心衰住院风险亦增高(aSHR 1.15)。
核心结论
- 房颤相关缺血性卒中的长期预后因房颤表型而异,AFIDA为高风险组,AFDAS为低风险组。
- 应将AFIDA与AFDAS视为不同的二级预防目标人群。
研究设计与样本
- 纳入2014年4月至2025年1月出院时处方OAC的成人房颤相关缺血性卒中存活者21,586例。
- 按房颤检测时机与既往抗凝状态分为AFIDA、OAC-naive AF和AFDAS三个互斥表型。
主要发现
- 中位年龄83岁(IQR 78-88),女性10,604例(49.1%)。
- AFIDA 6,604例(30.6%),OAC-naive AF 11,875例(55.0%),AFDAS 3,107例(14.4%)。
- 随访38,593人年,2,028例发生卒中/系统性栓塞。
- 5年卒中/系统性栓塞累积发生率:AFIDA 18.6%(95%CI 17.0%-20.2%),OAC-naive AF 13.0%(95%CI 12.0%-13.9%),AFDAS 10.5%(95%CI 9.0%-12.1%)。
- 与OAC-naive AF相比,AFIDA复发卒中/系统性栓塞风险更高(aSHR 1.38;95%CI 1.25-1.52),AFDAS更低(aSHR 0.87;95%CI 0.75-1.00);AFIDA心衰住院风险增高(aSHR 1.15;95%CI 1.02-1.31)。
临床怎么用
- 对AFIDA患者应识别为高危群体,强化二级预防策略。
- AFDAS患者复发风险相对较低,可考虑差异化抗栓管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Atrial fibrillation (AF)-associated ischemic stroke is often managed as a single clinical entity; however, prognosis may vary depending on whether AF was detected after the stroke or whether the stroke occurred despite prior oral anticoagulant (OAC) use. We aimed to describe long-term outcomes after ischemic stroke across 3 distinct AF phenotypes: AF complicated by ischemic stroke despite prior anticoagulation (AFIDA), AF complicated by ischemic stroke without prior anticoagulation (OAC-naive AF), and AF detected after stroke (AFDAS). METHODS: This nationwide cohort study used the DeSC-IQVIA database, an administrative claims database covering approximately 16 million individuals in Japan. Adult stroke survivors with AF discharged with OAC prescriptions between April 2014 and January 2025 were included. Three mutually exclusive AF phenotypes defined by AF detection timing and prior anticoagulation status: AFIDA, OAC-naive AF, and AFDAS (diagnosed during the index hospitalization). The primary outcomes were hospitalization for recurrent ischemic stroke or systemic embolism (SE). The secondary outcomes included major bleeding, heart failure (HF) hospitalization, and all-cause mortality. Cumulative incidence was estimated using the Aalen-Johansen method, accounting for the competing risk of death. Adjusted subdistribution hazard ratios (aSHRs) were estimated using Fine-Gray models. RESULTS: Among 21,586 patients (median age, 83 years [interquartile range (IQR), 78-88 years]; 10,604 [49.1%] female), 6,604 (30.6%) were classified as having AFIDA, 11,875 (55.0%) as having OAC-naive AF, and 3,107 (14.4%) as having AFDAS. During the 38,593 person-years of follow-up, 2,028 patients experienced stroke/SE. The 5-year cumulative incidence of stroke/SE was highest in AFIDA (18.6% [95% CI 17.0%-20.2%]), followed by OAC-naive AF (13.0% [95% CI 12.0%-13.9%]) and AFDAS (10.5% [95% CI 9.0%-12.1%]). Compared with OAC-naive AF, AFIDA was associated with a higher risk of recurrent stroke/SE (aSHR, 1.38; 95% CI 1.25-1.52), whereas AFDAS was associated with a lower risk (aSHR, 0.87; 95% CI 0.75-1.00). Among secondary outcomes, AFIDA showed an increased risk of HF hospitalization (aSHR, 1.15; 95% CI 1.02-1.31). DISCUSSION: Long-term prognosis after AF-associated stroke is heterogeneous across AF phenotypes, with AFIDA representing a high-risk group and AFDAS representing a low-risk group. These findings highlight the need to treat these clinically identifiable phenotypes as distinct target populations for secondary prevention strategies and future clinical trials.
引用
- Egashira S, Inoue K, Koga M, et al. Long-Term Outcomes After Ischemic Stroke Across Atrial Fibrillation Phenotypes Defined by Detection Timing and Prior Anticoagulation Status. Neurology. 2026. PMID: 42314108. doi:10.1212/WNL.0000000000218198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。